Lesson plan
Tagraxofusp
Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication used for the treatment of blastic plasmacytoid dendritic cell neoplasm. It is a CD123-directed cytotoxin. The most common adverse reactions include capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight increase. The most common laboratory abnormalities include decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST. Tagraxofusp is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin. The fusion protein readily kills cultured pDC by binding to their IL-3 receptors to thereby gain entrance to the cells and then blocking these cells' protein synthesis (due to its diphtheria toxin portion inhibiting eukaryotic elongation factor 2). It was approved for medical use in the United States in 2018, and in the European Union in January 2021. The US Food and Drug Administration considers it to be a first-in-class medication.
Article summary
Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication used for the treatment of blastic plasmacytoid dendritic cell neoplasm. It is a CD123-directed cytotoxin. The most common adverse reactions include capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight increase. The most common laboratory abnormalities include decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST. Tagraxofusp is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin. The fusion protein readily kills cultured pDC by binding to their IL-3 receptors to thereby gain entrance to the cells and then blocking these cells' protein synthesis (due to its diphtheria toxin portion inhibiting eukaryotic elongation factor 2). It was approved for medical use in the United States in 2018, and in the European Union in January 2021. The US Food and Drug Administration considers it to be a first-in-class medication.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.